down arrow

Artelo Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04301G5080
USD
2.06
0.26 (14.44%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.632.06

52 Week

1.5528.60
Valuation
Technical
Day's Volume

CASH

90.26 k

Shareholding (Mar 2025)

FII

0.01%

Held by 1 FIIs

DII

99.15%

Held by 1 DIIs

Promoter

0.00%

How big is Artelo Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Artelo Biosciences, Inc. has a market capitalization of 3.42 million, with net sales of 0.00 million and a net profit of -9.71 million over the latest four quarters. Shareholder's funds are 2.86 million, and total assets amount to 4.70 million.

As of Jun 18, Artelo Biosciences, Inc. has a market capitalization of 3.42 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -9.71 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 2.86 million and Total Assets of 4.70 million.

Read More

What does Artelo Biosciences, Inc. do?

22-Jun-2025

Artelo Biosciences, Inc. is a biopharmaceutical company focused on developing treatments that modulate the endocannabinoid system. It has a market cap of $3.42 million and reported a net profit loss of $2 million as of March 2025.

Overview: <BR>Artelo Biosciences, Inc. is a biopharmaceutical company focused on licensing, developing, and commercializing treatments that modulate the endocannabinoid system (ECS) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3.42 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.71 <BR>Return on Equity: -1,029.00% <BR>Price to Book: 3.42<BR><BR>Contact Details: <BR>Address: 888 Prospect St Ste 210, LA JOLLA CA: 92037-4261 <BR>Tel: 1 760 9431689 <BR>Website: http://artelobio.com/

Read More

Is Artelo Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Artelo Biosciences, Inc. shows a mildly bullish trend despite mixed technical signals and significant underperformance compared to the S&P 500, with a 1-month return of -43.03% and a 3-year return of -76.72%.

As of 12 August 2025, the technical trend for Artelo Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages show a mildly bullish stance, but the weekly Bollinger Bands and KST are mildly bearish. The Dow Theory indicates a bearish trend on the monthly timeframe. <BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a 1-month return of -43.03% versus the S&P 500's 2.33%, and a 3-year return of -76.72% compared to the S&P 500's 70.41%. Overall, the current stance is mildly bullish, but the strength is weak, with significant underperformance relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.88

stock-summary
Return on Equity

731.86%

stock-summary
Price to Book

-4.59

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-76.48%
0%
-76.48%
6 Months
-67.91%
0%
-67.91%
1 Year
-68.21%
0%
-68.21%
2 Years
-76.07%
0%
-76.07%
3 Years
-19.53%
0%
-19.53%
4 Years
-95.96%
0%
-95.96%
5 Years
-96.31%
0%
-96.31%

Artelo Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Artelo Biosciences, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Artelo Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages show a mildly bullish stance, but the weekly Bollinger Bands and KST are mildly bearish. The Dow Theory indicates a bearish trend on the monthly timeframe. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a 1-month return of -43.03% versus the S&P 500's 2.33%, and a 3-year return of -76.72% compared to the S&P 500's 70.41%. Overall, the current stance is mildly bullish, but the strength is weak, with significant underperformance relative to the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-6.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.27%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.67
EV to EBIT
-0.29
EV to EBITDA
-0.29
EV to Capital Employed
-2.96
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1029.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.84%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -33.33% vs -50.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.20",
          "val2": "-2.50",
          "chgp": "-28.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-2.40",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.38% vs 7.92% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.10",
          "val2": "-9.90",
          "chgp": "-2.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.60",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.80",
          "val2": "-9.30",
          "chgp": "-5.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.20
-2.50
-28.00%
Interest
0.10
0.00
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-3.20
-2.40
-33.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -33.33% vs -50.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.10
-9.90
-2.02%
Interest
0.00
0.00
Exceptional Items
0.30
0.60
-50.00%
Consolidate Net Profit
-9.80
-9.30
-5.38%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.38% vs 7.92% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Artelo Biosciences, Inc. stock-summary
stock-summary
Artelo Biosciences, Inc.
Pharmaceuticals & Biotechnology
Artelo Biosciences, Inc. is a biopharmaceutical company. The Company is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). It develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The Company is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The Company also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia).
Company Coordinates stock-summary
Company Details
888 Prospect St Ste 210 , LA JOLLA CA : 92037-4261
stock-summary
Tel: 1 760 9431689
stock-summary
http://artelobio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."